Jazz Pharmaceuticals Director Patrick Kennedy Receives Award

What Happened Patrick Kennedy, a director of Jazz Pharmaceuticals plc (JAZZ), received a grant of 1,605 restricted stock units (RSUs) on August 5, 2026. The filing reports an acquisition code A (award/grant) at $0.00 per unit (total reported consideration $0). Each RSU is a contingent right to receive one ordinary share upon vesting.

Key Details

• Transaction date: 2026-08-05 (Form 4 filed 2026-08-07; filing appears timely).
• Security/amount: 1,605 restricted stock units (RSUs); reported price per unit $0.00; total reported consideration $0.
• Vesting: Units will vest in full on July 23, 2027, subject to Kennedy’s continuous service and additional conditions (see footnote re: 2007 Non-Employee Directors Stock Award Plan).
• Plan: Granted under the Issuer’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• Shares owned after transaction: not specified in the provided filing text.
• Transaction code: A = Award/Grant.

Context RSUs are a form of equity compensation that convert to ordinary shares upon vesting; they are not an open-market purchase or sale and therefore do not directly signal buying or selling intent. This award appears to be routine director compensation tied to future service and conditions.